53 Design of the persuasive game ‘Ademgenoot’ 2 References 1. Price D, Fletcher M, van der Molen T. Asthma control and management in 8000 European patients: the REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey. NPJ Prim Care Respir Med. 2014;24:14009. doi:10.1038/npjpcrm.2014.9 2. Van Boven J, Lavorini F, Richard Dekhuijzen N. Urging Europe to put non-adherence to inhaled respiratory medication higher on the policy agenda: a report from the First European Congress on Adherence to Therapy. Eur Respir J. 2017;49:1700076. 3. Engelkes M, Janssens HM, de Jongste JC, Sturkenboom MC, Verhamme KM. Medication adherence and the risk of severe asthma exacerbations: a systematic review. Eur Respir J. 2015;45(2):396–407. doi:10.1183/09031936.00075614 4. Williams LK, Peterson EL, Wells K, et al. Quantifying the proportion of severe asthma exacerbations attributable to inhaled corticosteroid nonadherence. J Allergy Clin Immunol. 2011;128(6):1185–1191.e2. doi:10.1016/j.jaci.2011.09.011 5. Ebmeier S, Thayabaran D, Braithwaite I, Bénamara C, Weatherall M, Beasley R. Trends in international asthma mortality: analysis of data from the WHO Mortality Database from 46 countries (1993–2012). Lancet. 2017;390(10098):935–945. 6. Dekhuijzen R, Lavorini F, Usmani S, Van Boven O. Addressing the impact and unmet needs of nonadherence in asthma and chronic obstructive pulmonary disease: where do we go from here? Eur Respir J. 2018;6. 7. Guilbert TW, Garris C, Jhingran P, et al. Asthma that is not well-controlled is associated with increased healthcare utilization and decreased quality of life. J Asthma. 2011;48(2):126–132. doi:10.3109/02770903.2010.535879 8. Lasmar L, Camargos P, Champs NS, et al. Adherence rate to inhaled corticosteroids and their impact on asthma control. Allergy. 2009;64 (5):784–789. doi:10.1111/j.13989995.2008.01877.x 9. Looijmans-van den Akker I, Werkhoven A, Verheij T. Over-prescription of short-acting beta agonists in the treatment of asthma. Fam Pract. 2021;38(5):612–616. doi:10.1093/fampra/ cmab013 10. Bright IN, Magnus E, Pål H, Fredrik W, Gunilla T, Christer J. Overuse of shortacting β2-agonists in asthma is associated with increased risk of exacerbation and mortality: a nationwide cohort study of the global SABINA programme. Eur Respir J. 2020;55(4):1901872. doi:10.1183/ 13993003.01872-2019 11. Molina J, Plaza V, Nuevo J, Gutiérrez M, Sicras-Mainar A, Valero A. Clinical consequences of the overuse of short-acting β2-adrenergic agonists (SABA) in thetreatment of asthma in Spain: the SABINA study. Open Respiratory Archives. 2023;5(2). doi:10.1016/j. opresp.2023.100232 12. Doz M, Chouaid C, Com-Ruelle L, et al. The association between asthma control, health care costs, and quality of life in France and Spain. BMC Pulm Med. 2013;13:15. doi:10.1186/1471-2466-13-15 13. Dima AL, Hernandez G, Cunillera O, Ferrer M, de Bruin M. Asthma inhaler adherence determinants in adults: systematic review of observational data. Eur Respir J. 2015;45(4):994–1018. doi:10.1183/09031936.00172114 14. Horne R. Compliance, adherence, and concordance: implications for asthma treatment. Chest. 2006;130(1 Suppl):65s–72s. doi:10.1378/ chest.130.1_suppl.65S 15. Chapman S, Dale P, Svedsater H, et al. Modelling the effect of beliefs about asthma medication and treatment intrusiveness on adherence and preference for once-daily vs.
RkJQdWJsaXNoZXIy MTk4NDMw